Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease

NeuroImage
P VemuriAlzheimer's Disease Neuroimaging Initiative

Abstract

Our primary objective was to compare the performance of unaccelerated vs. accelerated structural MRI for measuring disease progression using serial scans in Alzheimer's disease (AD). We identified cognitively normal (CN), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI) and AD subjects from all available Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects with usable pairs of accelerated and unaccelerated scans. There were a total of 696 subjects with baseline and 3 month scans, 628 subjects with baseline and 6 month scans and 464 subjects with baseline and 12 month scans available. We employed the Symmetric Diffeomorphic Image Normalization method (SyN) for normalization of the serial scans to obtain tensor based morphometry (TBM) maps which indicate the structural changes between pairs of scans. We computed a TBM-SyN summary score of annualized structural changes over 31 regions of interest (ROIs) that are characteristically affected in AD. TBM-SyN scores were computed using accelerated and unaccelerated scan pairs and compared in terms of agreement, group-wise discrimination, and sample size estimates for a hypothetical therapeutic trial. We observed a number of systematic differences bet...Continue Reading

References

Nov 5, 1997·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·D K Sodickson, W J Manning
Jul 1, 1997·Neurobiology of Aging·W SilvermanJ Wegiel
Nov 22, 1997·IEEE Transactions on Medical Imaging·P A Freeborough, N C Fox
Oct 12, 2000·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·M A GriswoldA Haase
Jul 12, 2002·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Mark A GriswoldAxel Haase
Jun 20, 2003·Journal of Magnetic Resonance Imaging : JMRI·Jeffrey L GunterClifford R Jack
Nov 19, 2004·Topics in Magnetic Resonance Imaging : TMRI·Martin BlaimerPeter M Jakob
Feb 28, 2008·Journal of Magnetic Resonance Imaging : JMRI·Clifford R JackMichael W Weiner
Dec 2, 2008·Brain : a Journal of Neurology·E C MorminoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 21, 2009·Medical Physics·Jeffrey L GunterClifford R Jack
Sep 11, 2009·The New England Journal of Medicine·Liang-Wei Chen
Nov 17, 2009·NeuroImage·Frithjof KruggelUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Feb 9, 2010·Nature Reviews. Neurology·Giovanni B FrisoniPaul M Thompson
Mar 17, 2010·NeuroImage·Kelvin K LeungUNKNOWN Alzheimer's Disease Neuroimaging Initiative
May 11, 2010·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 14, 2010·Neurobiology of Aging·Shannon L RisacherUNKNOWN Alzheimer's Disease Neuroimaging Initiative (ADNI)
Jul 14, 2010·Neurobiology of Aging·J M SchottUNKNOWN Alzheimer's Disease Neuroimaging Initiative investigators
Jul 14, 2010·Neurology·P VemuriUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Feb 26, 2011·NeuroImage·Wesley K ThompsonUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 19, 2011·Psychiatry Research·Keith S CoverUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Aug 11, 2011·Human Brain Mapping·Dominic HollandUNKNOWN Alzheimer's Disease Neuroimaging Initiative
May 10, 2012·Journal of Magnetic Resonance Imaging : JMRI·Gunnar KruegerMatt A Bernstein
Nov 17, 2012·NeuroImage·Xue HuaUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 31, 2013·Neurology·Giovanni B FrisoniUNKNOWN ISTAART's NeuroImaging Professional Interest Area
Dec 3, 2014·Neurobiology of Aging·Christopher R K ChingUNKNOWN Alzheimer's Disease Neuroimaging Initiative

❮ Previous
Next ❯

Citations

Nov 8, 2015·Neurobiology of Aging·Xue HuaUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 13, 2016·Neurology·Susan M LandauUNKNOWN Alzheimer's Disease Neuroimaging Initiative
May 24, 2016·Current Opinion in Neurology·Prashanthi VemuriStefan Klöppel
Jun 15, 2019·Brain : a Journal of Neurology·Katerina A TetzloffJennifer L Whitwell
Mar 28, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 15, 2018·Brain : a Journal of Neurology·Clifford R JackRonald C Petersen
Jul 30, 2019·Journal of Alzheimer's Disease : JAD·Nicholas J TustisonUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jun 24, 2020·Brain : a Journal of Neurology·Irene SintiniJennifer L Whitwell
Feb 15, 2021·NeuroImage·Christopher G SchwarzUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 14, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Adam J Schwarz
May 22, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Liana G ApostolovaUNKNOWN LEADS Consortium
Jul 27, 2021·Journal of Alzheimer's Disease : JAD·Hidemasa TakaoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Sep 24, 2021·Journal of Magnetic Resonance Imaging : JMRI·Hidemasa TakaoUNKNOWN Alzheimer's Disease Neuroimaging Initiative

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Frank JessenGerman Study on Aging, Cognition and Dementia in Primary Care Patients
NeuroImage. Clinical
Ze WangAlzheimer's Disease Neuroimaging Initiative
Neurology
P VemuriAlzheimer's Disease Neuroimaging Initiative
© 2021 Meta ULC. All rights reserved